GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RxSight Inc (NAS:RXST) » Definitions » EV-to-EBIT

RxSight (RxSight) EV-to-EBIT : -47.90 (As of May. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is RxSight EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, RxSight's Enterprise Value is $2,168.69 Mil. RxSight's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-45.28 Mil. Therefore, RxSight's EV-to-EBIT for today is -47.90.

The historical rank and industry rank for RxSight's EV-to-EBIT or its related term are showing as below:

RXST' s EV-to-EBIT Range Over the Past 10 Years
Min: -47.9   Med: -6.13   Max: 10.46
Current: -47.9

During the past 5 years, the highest EV-to-EBIT of RxSight was 10.46. The lowest was -47.90. And the median was -6.13.

RXST's EV-to-EBIT is ranked worse than
100% of 460 companies
in the Medical Devices & Instruments industry
Industry Median: 20.215 vs RXST: -47.90

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. RxSight's Enterprise Value for the quarter that ended in Dec. 2023 was $1,332.97 Mil. RxSight's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-45.28 Mil. RxSight's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3.40%.


RxSight EV-to-EBIT Historical Data

The historical data trend for RxSight's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RxSight EV-to-EBIT Chart

RxSight Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -4.30 -4.81 -29.44

RxSight Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.81 -8.03 -16.59 -17.34 -29.44

Competitive Comparison of RxSight's EV-to-EBIT

For the Medical Devices subindustry, RxSight's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RxSight's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RxSight's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where RxSight's EV-to-EBIT falls into.



RxSight EV-to-EBIT Calculation

RxSight's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2168.694/-45.279
=-47.90

RxSight's current Enterprise Value is $2,168.69 Mil.
RxSight's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RxSight  (NAS:RXST) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

RxSight's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-45.279/1332.97464
=-3.40 %

RxSight's Enterprise Value for the quarter that ended in Dec. 2023 was $1,332.97 Mil.
RxSight's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RxSight EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of RxSight's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


RxSight (RxSight) Business Description

Traded in Other Exchanges
N/A
Address
100 Columbia, Aliso Viejo, CA, USA, 92656
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
Executives
Ilya Goldshleger officer: Chief Operating Officer C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Eric Weinberg officer: Chief Commercial Officer C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Shweta Maniar director C/O SEASPINE HOLDINGS CORP, 5770 ARMADA DRIVE, CARLSBAD CA 92008
Jesse Anderson Corley director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Kurtz Ronald M Md director, officer: See Remarks C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Robert Keith Warner director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Shelley B Thunen officer: Chief Financial Officer C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Bakker Juliet Tammenoms director LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Tamara Fountain director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Robert J Palmisano director 110 HARTWELL AVENUE, LEXINGTON MA 02173
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Julie Andrews director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116